Prostate cancer is the most common and among the most costly cancer in US men. Uncertainties regarding optimal management lead to treatment variations and increase cost. Accountable care organizations (ACO) can potentially improve care by decreasing variation (i.e. avoidance of treatment in low value settings) and constraining costs. Our objective was to determine the effect of Medicare Shared Savings Program (MSSP) ACOs on prostate cancer care.
INTRODUCTION AND OBJECTIVES:
Prostate cancer is the most common and among the most costly cancer in US men. Uncertainties regarding optimal management lead to treatment variations and increase cost. Accountable care organizations (ACO) can potentially improve care by decreasing variation (i.e. avoidance of treatment in low value settings) and constraining costs. Our objective was to determine the effect of Medicare Shared Savings Program (MSSP) ACOs on prostate cancer care.
METHODS: Using a 20% Medicare sample we perform a retrospective cohort study of men with newly diagnosed prostate cancer from 2010-2013. We assigned patients to ACOs based on their primary care provider's MSSP ACO participation. We then performed a difference-in-differences analysis comparing the impact of ACO participation on initial prostate cancer curative treatment, treatment of men with a very high 10-year non-cancer mortality risk (i.e. those least likely to benefit) and per beneficiary payments. Outcomes in the post-implementation period were compared to outcomes in the preimplementation.
RESULTS: We identified 33,461 men with incident prostate cancer of which 5,015 (15%) were assigned to an ACO. Overall, 58% of men were diagnosed in the pre-ACO implementation period. We noted secular trends in the non-ACO group from pre-to post-implementation in overall curative treatment (4.2% decline, p<0.001), treatment of men with the highest non-cancer mortality risk (6.2% increase, p¼0.11) and annual per beneficiary payments 4.0% decrease (p<0.001). ACO participation had no significant effect beyond the secular trend ( Figure) on overall treatment or annual payments (difference-in-differences estimator p¼0.8, p¼0.09, respectively). There was a significant relative decrease in treatment among men with the highest mortality risk of 17% (p¼0.03), however did this not lead to differences in cost.
CONCLUSIONS: Curative treatment of prostate cancer and annual per beneficiary payments decreased significantly between 2010 and 2013. For men diagnosed with prostate cancer, ACO participation did not impact trends in treatment or cost. However, among men least likely to benefit, ACOs resulted in a decline in treatment of prostate cancer.
Source of Funding: This work was supported by the American Cancer Society (RSG 12-323-01-CPHPS), the National Cancer Institute (R01 CA168691, R01 CA174768, T32 CA180984) and the National Institute on Aging (R01 AG048071).
PD32-04 SURGEON ENGAGEMENT IN EARLY ACCOUNTABLE CARE ORGANIZATIONS
Matthew Resnick*, Amy Graves, Melinda Buntin, Michael Richards, David Penson, Nashville, TN INTRODUCTION AND OBJECTIVES: Despite marked growth in Accountable Care Organizations (ACOs), little is known about either the magnitude of surgeon engagement or key drivers of surgeon engagement in early ACO programs. We aimed to characterize the landscape of surgeon engagement in early ACOs and identify specialty-, organization-, and market-factors associated with early ACO participation.
METHODS: Using data from SK&A, a commercial research firm, we evaluated independent, group, and integrated U.S. surgical practices, performing a cross-sectional analysis of 2015 ACO enrollment among 125,425 U.S. surgeons. We fit a multivariable logistic regression model to evaluate associations between ACO affiliation, surgical specialty, and organizational structure while adjusting for surgeon characteristics.
RESULTS: Of 125,425 U.S. surgeons, 27,956 (22.3%) reported enrollment in at least 1 ACO program in 2015. We identified significant heterogeneity in the proportion of ACO-enrolled surgeons by surgical specialty, with trauma and transplant reporting the highest magnitude of ACO enrollment, (36% for both) and plastic surgeons reported the lowest magnitude of ACO enrollment (12.9%) followed by ophthalmology (16.0%) and hand (18.6%). 22.8% of urologists reported at least 1 ACO contract. Practice organization was strongly associated with ACO enrollment, with surgeons in group practices and integrated health systems had higher odds of ACO affiliation relative to those practicing independently (aOR 1.57, 95% CI 1.50, 1.64; aOR 4.87, 95% CI 4.68, 5.07, respectively). We observed a statistically significant interaction (p<0.001) between surgical specialty and practice organization. Modelderived predicted probabilities revealed that, within each specialty, surgeons in an integrated health system had the highest predicted probabilities of ACO affiliation while those practicing in groups had smaller predicted probabilities and those practicing independently generally had the lowest. This pattern was largely consistent across surgical specialties. CONCLUSIONS: We observed considerable variation in ACO enrollment among U.S. surgeons. Observed variation appears to be largely mediated by differences in practice organization, with surgeons practicing in integrated health systems more likely to engage in ACO contracts than those in independent practice. Vol. 197, No. 4S, Supplement, Saturday, May 13, 2017 THE JOURNAL OF UROLOGY â e589
